SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee Therapeutics announced positive 52-week maintenance data from…

Apogee Therapeutics · PRESS-RELEASE filed Mar 23, 2026 at 06:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 23, 2026 at 06:30 ET

Apogee Therapeutics announced positive 52-week maintenance data from Part A of its Phase 2 APEX trial for zumilokibart (APG777), an anti-IL-13 antibody in moderate-to-severe atopic dermatitis. The drug showed durable and deepening responses with every 3- and 6-month dosing, supporting its potential as a best-in-class therapy with infrequent dosing. Phase 3 trials are expected to begin in the second half of 2026, with a potential 2029 commercial launch.

  • Zumilokibart demonstrated 75% and 85% maintenance of EASI-75 response at 52 weeks with every 3- and 6-month dosing, respectively.
  • vIGA 0/1 response was maintained in 86% (3-month) and 78% (6-month) of Week 16 responders.
  • Deepening of response observed across all lesional and itch endpoints in the full treated population, not just initial responders.
  • Drug was well tolerated with a safety profile consistent with class; most common TEAEs: noninfective conjunctivitis, URTI, nasopharyngitis.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access